{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963450",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963450_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bezafibrate\" outputclass=\"int-drug\">Bezafibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gallstones when given with</ph> <ph otherprops=\"ezetimibe\" outputclass=\"int-heading-drug\">ezetimibe</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if gallstones develops</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bezafibrate   is predicted to   increase   the risk of gallstones when given with   ezetimibe .  Manufacturer advises discontinue if gallstones develops .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bezafibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963451",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963451_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">Ciclosporin</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ezetimibe\" outputclass=\"int-heading-drug\">ezetimibe</ph> and <ph otherprops=\"ezetimibe\" outputclass=\"int-heading-drug\">ezetimibe</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/ciclosporin.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP529\">ciclosporin</xref></ph> concentration</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ciclosporin   moderately   increases   the exposure to   ezetimibe  and  ezetimibe   slightly   increases   the exposure to   ciclosporin .  Manufacturer advises caution and monitor  ciclosporin  concentration .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963452",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963452_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ciprofibrate\" outputclass=\"int-drug\">Ciprofibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gallstones when given with</ph> <ph otherprops=\"ezetimibe\" outputclass=\"int-heading-drug\">ezetimibe</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if gallstones develops</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ciprofibrate   is predicted to   increase   the risk of gallstones when given with   ezetimibe .  Manufacturer advises discontinue if gallstones develops .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963453",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963453_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fenofibrate\" outputclass=\"int-drug\">Fenofibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gallstones when given with</ph> <ph otherprops=\"ezetimibe\" outputclass=\"int-heading-drug\">ezetimibe</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if gallstones develops</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fenofibrate   is predicted to   increase   the risk of gallstones when given with   ezetimibe .  Manufacturer advises discontinue if gallstones develops .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963454",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2#bnf_i1643857963454_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"gemfibrozil\" outputclass=\"int-drug\">Gemfibrozil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gallstones when given with</ph> <ph otherprops=\"ezetimibe\" outputclass=\"int-heading-drug\">ezetimibe</ph>. <ph outputclass=\"int-action\">Manufacturer advises discontinue if gallstones develops</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Gemfibrozil   is predicted to   increase   the risk of gallstones when given with   ezetimibe .  Manufacturer advises discontinue if gallstones develops .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemfibrozil</title>"
					}
				}
			],
			"hasSearchLabel": " Ezetimibe  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/ezetimibe-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Ezetimibe </title>"
			},
			"rdfs:label": "ezetimibe"
		}
	]
}